SCHEMBL442765

SCHEMBL442765

O=C1[N]C=C(C(F)(F)F)C(=O)N1

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.30
PIM2 Q9P1W9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2047014 0.73
SCHEMBL3148463 0.65
SCHEMBL143917 0.65
SCHEMBL3148368 0.65
SCHEMBL440393 0.65
SCHEMBL438847 0.65 EEF2K (0.30)
SCHEMBL2042402 0.64 CES1 (0.32) PIM1PIM2
SCHEMBL8554982 0.62
SCHEMBL8552885 0.61
SCHEMBL545786 0.61 HKDC1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076310-B2 Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) 2011-12-13 US claimed
EP-0719273-B1 NUCLEOTIDE ANALOGS GILEAD SCIENCES INC (US) 2010-11-03 EP claimed
US-20100087387-A1 FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'-CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER CHATTOPADHYAYA JYOTI 2010-04-08 US claimed
US-7687500-B2 Substituted oxetanes, method of making, and method of use thereof THE UNIVERSITY OF CONNECTICUT (US) 2010-03-30 US claimed
EP-2134736-A1 FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'- CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER Chattopadhyaya, Jyoti (SE) 2009-12-23 EP claimed
WO-2008111908-A1 FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'- CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER CHATTOPADHYAYA JYOTI (SE) 2008-09-18 WO claimed
US-20080139566-A1 SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF HOWELL AMY R 2008-06-12 US claimed
JP-2007512358-A 2007-05-17 JP claimed
EP-1685127-A1 HETEROCYCLYL-SUBSTITUTED OXETANES FOR THE TREATMENT OF PROLIFERATIVE OR INFECTIOUS DISEASES The University of Connecticut (US) 2006-08-02 EP claimed
US-20050215568-A1 Substituted oxetanes, method of making, and method of use thereof UNIVERSITY OF CONNECTICUT, THE 2005-09-29 US claimed
WO-2005051944-A1 HETEROCYCLYL-SUBSTITUTED OXETANES FOR THE TREATMENT OF PROLIFERATIVE OR INFECTIOUS DISEASES UNIVERSITY OF CONNECTICUT (US) 2005-06-09 WO claimed
WO-2004106350-A1 NUCLEOSIDE ANALOGS AS VIRAL POLYMERASE INHIBITORS BIOCRYST PHARMACEUTICAL, INC. (US) 2004-12-09 WO claimed
US-20040242465-A1 Nucleotide analogs BISCHOFBERGER NORBERT W (US) 2004-12-02 US claimed
US-20040014722-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. 2004-01-22 US claimed
US-20010041794-A1 Nucleotide analogs GILEAD SCIENCES, INC. 2001-11-15 US claimed
US-6225460-B1 PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. GILEAD SCIENCES, INC. 2001-05-01 US claimed
US-5656745-A AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS GILEAD SCIENCES, INC. (US) 1997-08-12 US claimed
US-20230143643-A1 LOW DK COPPER CLAD LAMINATE COMPOSITIONS DESIGNER MOLECULES INC (US) 2023-05-11 US disclosed
US-4704392-A VIRICIDES SYNTEX (U.S.A.) INC. (US) 1987-11-03 US disclosed
US-4605659-A HERPES; HEPATITUS SYNTEX (U.S.A.) INC. (US) 1986-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242465-A1 Nucleotide analogs PNP, NUDT1, TYMP PIM1 3747/4885PIM2 4093/4885
US-20010041794-A1 Nucleotide analogs PNP, NUDT1, TYMP PIM1 3747/4885PIM2 4093/4885
US-20080139566-A1 SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF PNP, TYMP, DHPS PIM1 931/4885PIM2 1699/4885
US-20040014722-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases NSUN2, POLR2H, NSUN3 PIM1 2311/4885PIM2 1987/4885
US-20050215568-A1 Substituted oxetanes, method of making, and method of use thereof PNP, TYMP, DHPS PIM1 931/4885PIM2 1699/4885
US-20100087387-A1 FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'-CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER TYMS, NSUN2, RNMT PIM1 3573/4885PIM2 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.